Will the tills ring for Iovance?
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Lack of overall survival doesn't stop Flaura2
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
Carvykti joins Abecma in adcom limbo
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
